TabletsMRP Under Process
Official PMBI MRP is being updated for catalog code 2813.
Locate Jan Aushadhi KendraClinical Overview
Metformin Hydrochloride and Gliclazide (Modified Release) combines an insulin sensitizer with a selectively reversible sulfonylurea. Gliclazide selectively binds to pancreatic beta-cell SUR1 receptors with fast on-off association kinetics, restoring the physiological first-phase insulin secretory burst and offering lower hypoglycemia risk than glibenclamide, while metformin reduces hepatic glucose output. Indicated for type 2 diabetes mellitus when monotherapy provides insufficient glycemic control.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once daily with breakfast with water. Swallow whole; do not crush or chew modified-release tablets. Do not skip breakfast.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Hypoglycemia, dyspepsia, nausea, diarrhea, abdominal pain, headache. Rare/Severe: Lactic acidosis, prolonged hypoglycemia, and transient transaminitis.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Boxed warning for lactic acidosis. Contraindicated in severe renal failure (eGFR < 30 mL/min) and severe hepatic failure. Caution with alcohol consumption.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered endocrinologist, diabetologist, or qualified physician before initiating, adjusting dosages of, or substituting any antidiabetic or hormonal medication.
Metformin Hydrochloride Prolonged-release 500mg + Glimepiride 2mg Tablets
Metformin Hydrochloride and Glimepiride is a cornerstone dual-action antidiabetic combination on the WHO Model List of Essential Medicines. Metformin acts as an insulin-sensitizing biguanide that reduces excessive hepatic glucose output and improves peripheral glucose uptake without causing hypoglycemia or weight gain, while glimepiride acts as an insulin secretagogue, binding to SUR1 receptors on pancreatic beta-cell membranes to stimulate physiological postprandial insulin release. Indicated as an adjunct to diet and exercise in type 2 diabetes mellitus inadequately controlled by metformin alone.
Gliclazide Tablets 40 mg
Gliclazide (Modified Release 30 mg, 60 mg) is a second-generation oral sulfonylurea with selective pancreatic tropism on the WHO Model List of Essential Medicines. It selectively binds to SUR1 receptors with fast reversible kinetics, restoring early first-phase insulin secretion and protecting vascular endothelium against oxidative stress via free radical-scavenging properties. Modified-release tablets provide steady 24-hour glycemic coverage with low hypoglycemia and weight gain risk. Indicated for type 2 diabetes mellitus in adults.
Gliclazide Tablets 80 mg
Gliclazide (Modified Release 30 mg, 60 mg) is a second-generation oral sulfonylurea with selective pancreatic tropism on the WHO Model List of Essential Medicines. It selectively binds to SUR1 receptors with fast reversible kinetics, restoring early first-phase insulin secretion and protecting vascular endothelium against oxidative stress via free radical-scavenging properties. Modified-release tablets provide steady 24-hour glycemic coverage with low hypoglycemia and weight gain risk. Indicated for type 2 diabetes mellitus in adults.
Metformin Hydrochloride Sustained Release Tablets 1000 mg
Metformin Hydrochloride is the foundational first-line biguanide oral antihyperglycemic agent on the WHO Model List of Essential Medicines. It activates AMP-activated protein kinase (AMPK) in the liver, suppressing mitochondrial respiratory chain complex I, thereby potently inhibiting hepatic gluconeogenesis and glycogenolysis, while stimulating peripheral glucose uptake into skeletal muscle and delaying intestinal glucose absorption. Does not stimulate beta-cell insulin secretion, having zero intrinsic hypoglycemia risk and promoting weight neutrality or mild weight loss. Indicated as the initial pharmacological drug of choice for type 2 diabetes mellitus in adults and children aged 10 and older, and off-label in polycystic ovary syndrome (PCOS).